U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07863609) titled 'Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)' on Oct. 02.
Brief Summary: The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT). The study will also look at whether TX002100 reduces the need for blood or iron treatments, and whether it improves blood counts, such as hemoglobin levels.
Study Start Date: Jan. 31, 2027
Study Type: INTERVENTIONAL
Condition:
Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention:
BIOLOGICAL: TX002100
Subcutaneous injection
R...